LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Are depression and poor sleep quality a major problem in Turkish Women receiving chemotherapy for breast cancer?

    Buyuksimsek, Mahmut / Gulmez, Ahmet / Pirinci, Okan / Tohumcuoglu, Mert / Kidi, Mehmet Mutlu

    Revista da Associacao Medica Brasileira (1992)

    2024  Volume 70, Issue 3, Page(s) e20231377

    Abstract: Objective: The aim of this study was to evaluate depression and sleep quality in Turkish women receiving neoadjuvant or adjuvant chemotherapy for breast cancer and investigate their relationship.: Methods: This cross-sectional, descriptive, and ... ...

    Abstract Objective: The aim of this study was to evaluate depression and sleep quality in Turkish women receiving neoadjuvant or adjuvant chemotherapy for breast cancer and investigate their relationship.
    Methods: This cross-sectional, descriptive, and analytical study included 183 patients who received chemotherapy for non-metastatic breast cancer. Data were collected using the Beck Depression Inventory-II, the Pittsburgh Sleep Quality Index, and a disease-related/sociodemographic information form.
    Results: The mean age of the participants was 50.2 years, and 50.3% were in menopause. The mean Beck Depression Inventory-II score was 19.64±10.4. Mild depression was detected in 25.7% (n=47) of the women, and moderate or severe depression in 55.2% (n=101). The mean global score of sleep quality was found to be 8.28±2.62, and the majority of the participants (79.7%, n=146) had poor sleep quality. There was a positive correlation (p<0.001, r=0.43) between depression and sleep quality scores. While a negative correlation was found between depression scores and age (p<0.001, r=0.26), the surgical procedure performed did not significantly affect depression scores (p=0.705). Additionally, depression scores were positively correlated with sleep duration (p<0.001, r=0.42) and sleep latency (p=0.01, r=0.48).
    Conclusion: Very high rates of depression and poor sleep quality were detected among Turkish women receiving neoadjuvant or adjuvant chemotherapy for breast cancer. The entire healthcare team involved in the treatment process should take this relationship into consideration and use the necessary preventive and therapeutic methods.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Middle Aged ; Cross-Sectional Studies ; Turkey/epidemiology ; Adult ; Depression/epidemiology ; Chemotherapy, Adjuvant/adverse effects ; Sleep Quality ; Sleep Wake Disorders/epidemiology ; Aged ; Psychiatric Status Rating Scales ; Surveys and Questionnaires ; Socioeconomic Factors ; Severity of Illness Index ; Neoadjuvant Therapy/adverse effects
    Language English
    Publishing date 2024-04-22
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20231377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer.

    Yetişir, Abdullah Evren / Paydaş, Semra / Büyükşimşek, Mahmut / Oğul, Ali / Kolsuz, İrem / Kıdı, Mehmet Mutlu

    Journal of cancer research and therapeutics

    2023  Volume 20, Issue 1, Page(s) 285–288

    Abstract: Background: To evaluate the relationship of overall survival (OS) and progression-free survival (PFS) with the derived neutrophil-lymphocyte ratio (dNLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), and platelet-lymphocyte ratio ( ...

    Abstract Background: To evaluate the relationship of overall survival (OS) and progression-free survival (PFS) with the derived neutrophil-lymphocyte ratio (dNLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), and platelet-lymphocyte ratio (PLR) in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
    Methods: The study included 43 patients with EGFR-mutant metastatic NSCLC. The dNLR, NLR, LMR, and PLR values were calculated using the baseline complete blood counts before and after treatment with erlotinib.
    Results: The NLR value had the best diagnostic test performance with a sensitivity of 91.3%. dNLR, NLR, LMR, and PLR were found to be significant for the prediction of OS and PFS. While the delta dNLR and NLR values were significant for OS, only the delta NLR value was significant for PFS.
    Conclusions: The dNLR, NLR, LMR, and PLR values were found to be significant in the prediction of OS and PFS in erlotinib-treated metastatic NSCLC. Further clinical studies are needed to determine the ideal target-specific tyrosine kinase inhibitor in cases of metastatic NSCLC presenting with the EGFR-activating mutation.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Erlotinib Hydrochloride/therapeutic use ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Retrospective Studies ; Prognosis ; Lymphocytes/pathology ; Neutrophils/pathology ; ErbB Receptors/genetics
    Chemical Substances Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1) ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-04-06
    Publishing country India
    Document type Journal Article
    ZDB-ID 2187633-2
    ISSN 1998-4138 ; 0973-1482
    ISSN (online) 1998-4138
    ISSN 0973-1482
    DOI 10.4103/jcrt.jcrt_1858_22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.

    Ogul, Ali / Kidi, Mehmet Mutlu / Buyuksimsek, Mahmut

    Journal of gastrointestinal cancer

    2020  Volume 52, Issue 1, Page(s) 294–299

    Abstract: Objective: It is known that chronic inflammation plays an important role in the etiopathogenesis of biliary tract carcinoma (BTC). In this study, we wanted to examine the effect of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ... ...

    Abstract Objective: It is known that chronic inflammation plays an important role in the etiopathogenesis of biliary tract carcinoma (BTC). In this study, we wanted to examine the effect of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), and prognostic nutritional index (PNI) on survival in advanced BTC treated with gemcitabine plus cisplatin (GEMCIS) regimen.
    Methods: Forty-two patients with advanced BTC treated with GEMCIS regimen were included in the study. Measurements for NLR, dNLR and PNI were calculated with available formulas. NLR, dNLR, and PNI values were dichotomized based on receiver operating characteristic curve analysis (cut-off values 3.94, 2.66, and 46, respectively). Univariate and multivariate analyses were performed to identify prognostic factors for 6-month progression free survival (PFS) and overall survival (OS) using a Cox proportional hazards model.
    Results: The mean PFS was 5.3 (median 5) months, and the mean OS was 10.7 (median 11) months. The pre-treatment increased NLR (≥ 3.94) value was prognostic for lower 6-month PFS and 12-month OS rates. dNLR was not found to be important for survival times. Low PNI (< 36) value was prognostic for lower 6-month PFS and 12-month OS rates. In the multivariate analysis, increased NLR value was determined as an independent prognostic factor for 6-month PFS.
    Conclusion: In patients with advanced BTC using GEMCIS as the first-line chemotherapy regimen, NLR and PNI can be used as prognostic inflammatory markers for 6-month PFS and 12-month OS.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Biliary Tract Neoplasms/blood ; Biliary Tract Neoplasms/diagnosis ; Biliary Tract Neoplasms/drug therapy ; Biliary Tract Neoplasms/mortality ; Carcinoma/blood ; Carcinoma/diagnosis ; Carcinoma/drug therapy ; Carcinoma/mortality ; Cisplatin/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Humans ; Inflammation/blood ; Inflammation/diagnosis ; Inflammation/immunology ; Kaplan-Meier Estimate ; Lymphocyte Count ; Lymphocytes/immunology ; Male ; Middle Aged ; Neoplasm Staging ; Neutrophils/immunology ; Prognosis ; Progression-Free Survival ; Retrospective Studies
    Chemical Substances Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2020-06-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2452514-5
    ISSN 1941-6636 ; 1559-0739 ; 1941-6628 ; 1537-3649
    ISSN (online) 1941-6636 ; 1559-0739
    ISSN 1941-6628 ; 1537-3649
    DOI 10.1007/s12029-020-00428-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer.

    Yetişir, Abdullah Evren / Paydaş, Semra / Büyükşimşek, Mahmut / Oğul, Ali / Yaprak, Özge / Zorludemir, Suzan / Ergin, Melek / Kolsuz, İrem / Kidi, Mehmet Mutlu

    Revista da Associacao Medica Brasileira (1992)

    2023  Volume 69, Issue 1, Page(s) 153–158

    Abstract: Objective: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant ... ...

    Abstract Objective: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Methods: A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated.
    Results: The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined.
    Conclusion: In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response.
    MeSH term(s) Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Enhancer of Zeste Homolog 2 Protein/genetics ; Mucin-1/genetics ; Neoplasm Staging ; Receptor, ErbB-2/metabolism
    Chemical Substances Enhancer of Zeste Homolog 2 Protein (EC 2.1.1.43) ; Mucin-1 ; Receptor, ErbB-2 (EC 2.7.10.1) ; EZH2 protein, human (EC 2.1.1.43) ; MUC1 protein, human
    Language English
    Publishing date 2023-02-17
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20221123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Brigatinib-associated autoimmune hepatitis: A case report.

    Buyuksimsek, Mahmut / Ogul, Ali / Yetisir, Abdullah Evren / Duman, Berna Bozkurt / Tohumcuoglu, Mert / Cil, Timucin / Koseci, Tolga / Kidi, Mehmet Mutlu / Sumbul, Hilmi Erdem

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2023  , Page(s) 10781552231171322

    Abstract: Introduction: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrangements. While pancreatic enzyme elevations due to brigatinib are well known, we wanted to present a ... ...

    Abstract Introduction: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrangements. While pancreatic enzyme elevations due to brigatinib are well known, we wanted to present a case that caused liver toxicity.
    Case report: ALK and ROS1 translocations were detected in a 58-year-old patient diagnosed with metastatic lung adenocarcinoma. In the patient who had a good response with brigatinib, more than 5-fold elevation was detected in liver enzymes at the fifth month of treatment.
    Management & outcome: After excluding other hepatitis factors, the patient was thought to have autoimmune hepatitis, and methylprednisolone was started and liver enzymes were decreased.
    Discussion: Increased creatine kinase and lipase levels are common side effects associated with brigatinib, while liver toxicity is rare. Autoimmune hepatitis due to brigatinib was considered because of hepatic toxicity that developed in the fifth month of treatment and responded well to steroids.
    Language English
    Publishing date 2023-04-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/10781552231171322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4488: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen.

    Buyuksimsek, Mahmut / Kidi, Mehmet Mutlu / Ogul, Ali / Mirili, Cem / Paydas, Semra

    Journal of gastrointestinal cancer

    2020  Volume 52, Issue 1, Page(s) 249–255

    Abstract: Background: In advanced biliary tract carcinoma (BTC), the prognosis is very poor, and the overall survival is less than 1 year. This study aimed to determine the effect of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio ( ... ...

    Abstract Background: In advanced biliary tract carcinoma (BTC), the prognosis is very poor, and the overall survival is less than 1 year. This study aimed to determine the effect of neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), C-reactive protein (CRP)/albumin ratio (CAR), and prognostic nutritional index (PNI) on the survival of BTC patients treated with gemcitabine/oxaliplatin (GEMOX) regimen.
    Methods: Data of 53 patients with advanced BTC were evaluated retrospectively. Association between inflammatory markers and 6-month PFS and 12-month OS were compared by the log-rank test. The optimal cutoff values were determined by a receiver operating characteristic (ROC) curve analysis. NLR, dNLR, CAR, and PNI were grouped based on cutoff points 1.95, 1.15, 0.57, and 33, respectively. Univariate and multivariate analyses were used to assess their prognostic values for survival.
    Results: Lower dNLR (< 1.15) was prognostic for higher 6-month PFS and 12-month OS rates, while lower NLR (< 1.95) was prognostic for higher 6-month PFS rates only. CAR and PNI did not have statistically significant effects on survival.
    Conclusions: Pretreatment dNLR and NLR values in advanced BTC can be used as predictive markers for survival in patients undergoing the GEMOX regimen.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biliary Tract Neoplasms/blood ; Biliary Tract Neoplasms/drug therapy ; Biliary Tract Neoplasms/immunology ; Biliary Tract Neoplasms/mortality ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/immunology ; Carcinoma/blood ; Carcinoma/drug therapy ; Carcinoma/immunology ; Carcinoma/mortality ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Inflammation/blood ; Inflammation/diagnosis ; Inflammation/immunology ; Lymphocyte Count ; Lymphocytes/immunology ; Male ; Middle Aged ; Neutrophils/immunology ; Nutrition Assessment ; Organoplatinum Compounds/therapeutic use ; Prognosis ; Progression-Free Survival ; Risk Assessment/methods
    Chemical Substances Biomarkers, Tumor ; Organoplatinum Compounds ; Deoxycytidine (0W860991D6)
    Language English
    Publishing date 2020-03-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2452514-5
    ISSN 1941-6636 ; 1559-0739 ; 1941-6628 ; 1537-3649
    ISSN (online) 1941-6636 ; 1559-0739
    ISSN 1941-6628 ; 1537-3649
    DOI 10.1007/s12029-020-00396-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top